- Conditions
- Arthritis, Juvenile
- Interventions
- Golimumab, Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 14
- States / cities
- San Diego, California • Chicago, Illinois • Boston, Massachusetts + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Juvenile Idiopathic Arthritis (JIA)
- Interventions
- Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- CP-690,550 (tofacitinib), placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 55
- States / cities
- Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
- Conditions
- Juvenile Idiopathic Arthritis, JIA
- Interventions
- adalimumab, Methotrexate
- Biological · Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 849 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 6 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Washington D.C., District of Columbia • Delray Beach, Florida + 7 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Sarilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
- Interventions
- Certolizumab Pegol (CZP)
- Drug
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
- Interventions
- TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more